HUGE. Human Placental-Derived Adherent Stromal Cells

alloon, we should see Phase III in about 12 years or so... I'll bet YOU are HUGE.

kiki27
Monday, 07/23/18 02:23:43 PM
Re: None
0
Post # of 14011

One thing that gives me confidence in Pluristem is that I have yet to see a negative result from any of their trials or studies. We have a potential of billions in revenue to treat conditions for which there is presently no viable treatments. I'll hold onto my shares.


Pre Eclampsia
Not even on the radar (Slide 13)... FAILURE! - especially with what we got out of the trial... Women suffering needlessly because of GREED.
See for yourself:
https://seekingalpha.com/article/3859416-pluristems-placental-cells-prove-superior-pre-eclampsia-leading-cause-maternal-fetal-death

EXPECTED MILESTONES PLX-R18

FDApproved
Saturday, 07/08/17 07:21:07 PM
Re: None
0
Post # of 13998

EXPECTED MILESTONES PLX-R18



•Initiation of pivotal study in ARS-H2/2017/H1/2018

•Contract with U.S.Government for ARS-H2/2017

•Data readout phase I open label HCT-H2/2017

•Preclinical data Fukushima-H2/2017

•Preclinical data NYBC-H2/2017

FDApproved
Tuesday, 06/20/17 11:38:02 AM
Re: None
0
Post # of 13997

Pluristem Will Be Profitable The Day The PLX-R18 Government Stockpiling Contract Is Sign Any Day Now !

GIDDY-UP !

Someone please explain why we are NOT seeing revenue via EAP where there are @ 2M +/- CLI patients that are "unsuitable" for revascularization... Why aren't we helping these patients NOW?!

Critical limb ischemia (CLI)-severe pain at rest, skin wounds, tissue necrosis and poor quality of life with a high risk of leg amputation and death • Up to 40% of patients are unsuitable for revascularization and experience up to a 40% amputation rate at 1 year* • 5-6 million patients in U.S. and Europe suffer from CLI. Estimated cost of treatmentinU.S.aloneisover$25billionperyear** • Expanded Access Program cleared by U.S.FDA for the treatment of CLI patients that are unsuitable for inclusion under the PhaseIII study protocol

Excellent comparison...

alloooooon. Well played.


https://www.prnewswire.com/news-releases/shareholder-class-action-filed-against-osiris-therapeutics-inc----osir-300205247.html

https://finance.yahoo.com/news/lawsuit-investors-osiris-therapeutics-inc-160000279.html

zzatt, please

put me back on mute!

PS, I knew you couldn't stay away.

Think we'll see

the 10Q before September?

Hopester...IMO..The Main Reason

Amazing explanation for the weakness in out stock... 'A mere few hundred shares, daily keeps us from going to Infinity and beyond, eh?'

For a better explanation of what is going on, see below.

FDApproved
Friday, 07/20/18 12:50:27 PM
Re: None
0
Post # of 13923

Hopester...IMO..The Main Reason The Stock Is Has Been And Is Currently At $1.29 Is Precisely The Opposite Of Your Worries About Big Pharma ! It's The Big Pharma'a That Are Very Worried About Pluristem Removing Billions Of Dollars Over The Coming Years From Their Bottom Line And Their Lucrative Products That Only Treat The Symptoms Of A Disease.

If You Take The Time To Study FINERA's Website And The Dark Pool Trading, You Will See Clear Evidence Of 2 Foreign Banks Basically Controlling Pluristem's Stock With Dozens And Even Hundreds Of Trades A Day From 100 to 300 Shares A Day. The Evidence is Right There For All To See And Apparently It Is Being Done In A Legal Fashion ?

I Predict The Day Will Come When Upon Pluristem's First FDA Approval We Will See A Big Pharma Attempt A Hostile Take-Over. My Gut Feeling Is Pluristem Is Well Aware Of This As Their Own Attorney Oded Har Even Spoke About It On June 27th In An Article In The Globes. See Link Below. Look For Their Attorney's Quote About A Potential Hostile Take-Over. Their Attorney Is Oded Har Even. Carefully Read And Try To Fully Understand What These Men Are Talking About, As It Will Give You A Clear View Into Their Thinking And What May Be Coming Soon ? (aMoon) Enjoy...

https://translate.google.com/translate?hl=en&sl=iw&u=https://www.globes.co.il/news/article.aspx%3Fdid%3D1001243128&prev=search

You are confused, zzaatt. The 'Market' has its own influences, just like the economy, and many they share. Including Competition...

Cell therapy, Stem Cells, and their pursuers, etc. Etc. are not 'secrets' or 'hiding'... and certainly NOT psti given its pvs fraud history and poster child for pump and dump. IMHO.

Even with approval announcements and failures, the Markets move ahead of the science. Please do some research, look at the charts and trends ahead of announcements and try to become one of the ones who is in the know before everyone else.

Pulling into port, gotta go.

Cheers.

Cheers!

This is TOO easy... Now that she can't post anymore today...

Remember what alloon just posted... "Market has No Clue about PSTI" OMG...

FDApproved
Tuesday, 05/09/17 09:28:17 AM
Re: None
0
Post # of 13864

May 9, 2017 H.C. Wainwright They currently have a $3.50 price target on the biotechnology company’s stock


https://transcriptdaily.com/2017/05/09/hc-wainwright-reiterates-buy-rating-for-pluristem-therapeutics-inc-psti.html

"The Market Doesn't Have A Clue About Pluristem !"

Now this one... this one is DEFINITELY a LAGGING INDICATOR and IRRITATOR. I'll try to help others figure her out, before they are deceived...


XOXO

The "market" in not some mystical entity with deep knowledge and
insight into the potential value and the science that will define Pluristem's
future. Once more: the market is a lagging indicator!!!

Sorry, FALSE. Not ALWAYS... While not a 'mystical entity' it INDEED is a collection of "deep knowledge and insight into the potential value and the science that will define Pluristem's (insert ANY publicly traded entity) future." It is NOT ALWAYS a lagging indicator.

Look what the 'markets' have done as a LEADING indicator for the current economy...….. educated speculation, OTHERWISE, how do you explain the jump post election, FACTS or SPECULATION?

Analysts, Insiders, MDs, Scientists, etc., etc. make their livings 'moving' the 'market', up and down, stock by stock, through 'educated speculation'

The "market" says the Apple is very valuable. The "market" did NOT
tell anyone that it will be a massive success twenty years ago.

Sorry, FALSE, again. Simply NOT TRUE.
In the case of Apple, MANY, MANY, MANY analysts/brokers saw the future of Apple and encouraged buying and speculation. (including MY broker...and I have Millions of reasons) why I still like my broker.

I commend you for your passion if not for your facts.

Cheers!

IF iffs and butts...

Can you trust this?!?!

FDApproved
Tuesday, 05/09/17 04:06:58 PM
Re: None
0
Post # of 13857

China Deal.....

According To Last Nights 10Q, It States Both The China Deal With Innovation Medical As Well As The Sosei Deal In Japan Both Have Until June 30, 2017 To Close The Deal. My Guess Is They Both Get Done By The End Of June. That Will Bring Pluristem's Cash On Hand To Approximately 58 Million.

Agreed. Even the "Investor Relations MD" doesn't impress.

Or... Is it another
Non-event, and the last 3% up/down was enough of a channel for some day traders to make a few bucks, and they are doing it again.

Don't over think it allo on.

Of course, you could always trust these genius, researched speculations...

Alloon = FDApproved
Monday, 05/08/17 05:17:15 PM
Re: None
0
Post # of 13838

Does This Mean They Got Deal Done ???

Otherwise, Why Do This Today And Not During The First Quarter ?

S-8 Registration of Shares under the Pluristem Therapeutics Inc. 2016 Equity Compensation Plan

In connection with the registration under the Securities Act of 1933, as amended (the “Act”), by Pluristem Therapeutic Inc., a Nevada corporation (the “Company”), of 5,363,000 shares of its
common stock, par value $0.00001 per share (“Common Stock”), that are to be issued under the Company’s 2016 Equity Compensation Plan (the “2016 Plan”) and the Company’s Amended and
Restated 2005 Stock Option Plan (the “2005 Plan” and collectively with the 2016 Plan referred to as the “Plans”), including shares of common stock issuable upon the exercise of options and
vesting and exercise of restricted stock units (“RSUs”) granted and to be granted pursuant to the provisions of the Plans (all such shares issued or to be issued thereunder referred to herein as,
the “Registered Shares”), the following opinion is furnished to you to be filed with the Securities and Exchange Commission (the “Commission”) as Exhibit 5.1 to the Company’s Registration
statement on Form S-8 (the “Registration Statement”) under the
Act.

https://www.sec.gov/Archives/edgar/data/1158780/000117891317001319/zk1719893.htm

Still no Scotty here, alloon.

Not even close. The fact that it bothers YOU is motivation enough.

CHANGE is coming...

Nice to the ONLY physician at psti (Dr.K) now has a blog - how many years has she been there? Dr. K was an OBGYN, how'd our studies go in OBGYN again, alloon?

FDApproved
Thursday, 07/19/18 10:10:37 AM
Re: None
0
Post # of 13837

Scotty..Take A Break, Your Leadership Change Posting Is A Fantasy !

"improvement in maximal walking distance from baseline was 42% better (p=.043) versus the placebo group....

The need for vascular surgery was eliminated through week 65 in patients who received the optimal dosing regimen."

zzatt: the market DOES read the data, and they have responded...

Here is the problem with this data:
1) MWD is still a HIGHLY variable, SUBJECTIVE to human judgement, & placebo affected measurement!!! - AND our pvalue was 'barely', .007, statistically significant. THIS SHOULD BE THE "LAYUP" measurement we MOST significantly impact in a PAD study
2) There is NO $$ value (savings to system, QOL?, or other breakthrough) in this result.
3) NO 'significant' revascularization that eliminated the need for AMPUTATIONS and surgery... (The most critical endpoint of all) Thus -"The need for vascular surgery was eliminated through week 65 (1year, 3mo.)"
notice NO P-value touted here...???

There are MANY, MANY

others just like us, zzatt! The Drum Beat is growing....

WE (patients) need a change in leadership.

MR JEFFS, Please take the Helm and right this ship!



zzaatt
Thursday, 07/19/18 09:42:14 AM
Re: hopester post# 13825
0
Post # of 13831

Quote:

Seems I'm not the only one questioning the credibility of the of the mgmt

We were supposed to be able to do this ON OUR OWN! - Not only for our own products, but for the future of cell medicine... The "genius" of Zami the Swami to invest a '2-year delay' to all clinical trials to monopolize 3D manufacturing is proving to be another FAILURE, either in expectations, or ability, or worse...


What impact are we seeing NOW from leaderships decisions to delay product development for 2years (revenue yesterday, today, …) in order to have a "manufacturing monopoly"????????????????????????


Common Sense is a rare as Genius… Right?!


FDApproved
Wednesday, 07/18/18 10:43:18 PM
Re: None
0
Post # of 13829

The collaboration combines Thermo Fisher’s experience in cell therapy development and bioproduction scaleup with Pluristem’s expertise in cell therapy manufacturing, clinical development and quality control. Together, the companies hope to transform cell therapy manufacturing into a large-scale, high capacity industry that will enable the production of millions of therapeutic doses of regenerative medicines.


Pluristem Was Able To Partner With The Biggest/Best Company !

The Market Is Clueless Until They Finally Get A Clue !

Agreed X10 - and as such, all present and future 'communications' - content, vehicle, messenger(s) will be meticulously dissected for fact and value VS. speculation, distraction and SPIN.

hopester
Wednesday, 07/18/18 06:45:55 PM
Re: Auto1 post# 13816
0
Post # of 13828

I say the credibility of all past statements made by PSTI from mgmt is at least called into question and suspect.
And the market agrees with you. They're paying little heed to all the feed and bait they've thrown out.
Yet I'm not ready to sell it as we just don't know that all of it is dismissible.
I spoke of charts in prior posts. It will tell us.
FOR NOW
The aroma of the perfume has been overcome by the stench of statements.

alloon is out of posts today...

Funny... No mention here of needing
a manufacturing partner for "The Cure"... nope. I checked twice.


He should go back to corporate secretary. A vote of NO-CONFIDENCE is in order.


Is it Deceit or Incompetence? - What say you?



FDApproved
Monday, 05/08/17 07:21:26 AM
Re: None
0
Post # of 13815


Sitting on stage at The Jerusalem Post Annual Conference in New York on Sunday.

(He Is Here In The USA !) That's A Good Sign !


Innovator Yaky Yanay pulled a small glass vial out of his pocket – promising a solution to Iranian nuclear threats.

“I have the solution in my pocket,” said Yanay, CEO and president of Pluristem Therapeutics.


The Haifa-based company, which aims to create “the next generation of biological therapeutic products,” specializes in harnessing placental cells to treat a variety of diseases using a three-dimensional platform. For one such ailment that Pluristem is targeting, Acute Radiation Syndrome, the company is currently conducting dose evaluation studies with the US National Institutes of Health’s NIAID PLX-R18 cells – the same cells in Yanay’s glass vial.

“If we can inject these cells after exposure to radiation, we will be able to keep the entire population alive,” he said.

As Pluristem continues to delve into cell therapy research, the company is focusing on increasing longevity in the face of illnesses that today have no viable treatments. In addition, the company expressed hopes that the introduction of cell therapies could cut government healthcare costs significantly while improving care – offering accessible, safe and effective treatments.

“The world is aging dramatically,” Yanay said. “We’ve doubled life expectancy in past 150 years and we need new technologies.”


http://www.jpost.com/Diplomatic-Conference/A-biological-solution-to-the-Iranian-threat-490067

"We have the capacity to make 150,000 doses of commercial grade PLX cells at this time, and to increase capacity we need only scale out with additional bioreactors."


Doesn't sound like a 'media issue'... despite alloon's desperate attempts to spin away more leadership failure and a completely unqualified co-ceo duo.


At some point, what they communicate is just BLATENTLY False.



Spin baby Spin.

The 5pm LAUGH - brought to you by...

Note the date and psychic author alloon. Makes me giggle everytime I read it...….

Accountants impersonating Medical Science Professionals, the STREET laughs AT us, not WITH us...

FDApproved
Saturday, 05/06/17 08:05:08 PM
Re: None
0
Post # of 13813

Scaling-Up PLX-Cell Production Will Not Be An Issue For Pluristem
Excerpt From An Interview With Yaky Yanay Last November 29th

"Commercial manufacturing is a critical bottleneck in the space. Many people are now focused on this challenge, because if new technology is needed to produce commercial quantities of cells, one runs the risk of changing the cell characteristics by growing them with different technology. In contrast with others in our space, we have our own FDA and EU-approved manufacturing facility through commercialization meaning if and when our products reach approval, we are already cleared to use our own manufacturing facilities to commercialize them. We have the capacity to make 150,000 doses of commercial grade PLX cells at this time, and to increase capacity we need only scale out with additional bioreactors. We do not need to modify the patented production technology. We can make 20,000 doses from a single placenta, and this efficiency is because of our patented manufacturing technology and our placental cell source."

https://marketexclusive.com/exclusive-interview-pluristem-therapeutics-inc-nasdaqpsti-president-yaky-yanay/41188/

No Scotty here...alloon.

No kidding, really?!?!

What is the deal that PSTI has like that, again? We All must have missed that memo.

FDApproved
Wednesday, 07/18/18 04:38:43 PM
Re: None
0
Post # of 13811

Scotty...The 500 Million Is In Milestone Payments ! They Did Not Get That Much Up-Front.

Anyone else have an issue with PSTI, based on alloon's post below?!?!

"What’s Revolution got? Its lead program is a preclinical-stage small molecule that might fight cancer in two separate ways."

Revolution just got paid $500M for a "preclinical-stage small molecule that "'MIGHT" fight cancer..." $500Million...


While in psti'ville, we have the "CURE" for ARS Death - "In Our Pocket" - "Approved" by the FDA (conditional), which includes "stockpiling" - without 1 single order... and cannot get a deal with ANYBODY...

If this doesn't scream FAILURE by leadership, what does?? This is what happens when you put an Accountant in a CEO position in front of Analysts and Physicians to speak about medical science, patients and mechanisms of action... Its a pitiful joke. These guys couldn't sell a cure for ARS in a Nuclear Holocost… LITERALLY!


$500Million for a pre-clinical, small molecule. THINK ABOUT IT FOLKS

https://endpts.com/antifungal-out-cancer-in-revolution-scores-500m-sanofi-deal-on-first-oncology-program/

FDApproved
Saturday, 05/06/17 12:33:50 PM
Re: None
0
Post # of 13623

This Is Allo On The Investor Hub Board !

Great Find Blue ! I Have Been Trying To Post Some Items Since Yesterday Afternoon ! The " Controller" Has Shut Down The PSTI Yahoo Message Board. It's The Only Board Affected On Yahoo ! All Other Boards Are Working ! Wow, They Will Stop At Nothing To Silence The Truth ! We Must Be Very Close To A Mega Deal ?

I Agree It Appears We Are At A MAJOR TURNING POINT IN THE HISTORY OF PLURISTEM ! Everything Seems To Be Coming Together All At Once ! Check This FDA POST OUT FROM LAST NIGHT ! The FDA Just Approved a Drug For ALS That Was Just Approved In Japan After Just One 6 Month Clinical Trial With Good Data ! That Speaks Volumes As To How A Drug With Good Data Can Now Be Approved For A Major Unmet Need ! Pluristem Fits That Bill Perfectly ! We May Have Our First Approval By The End Of This Year ? ~ Allo~

allo's serum free media and leap that this was the reason...

IS JUST FAKE SPIN NEWS!!! Stay tuned, I'll show you why... In her Own Words..


Buckle Up, Buttercup!

Thunderforce1, you are very confused.

NOBODY, check the history, has ever questioned the efficacy or potential of the science or products... so your argument is invalid.

What is questioned, based on facts and data, are the qualifications, experience, history and track record of the current leadership to expedite negotiations with the FDA, Develop a Commercialization Strategy, and Manufacture with GMPP a reliable and robust commercial supply of drug for the 'Millions' of patients that have been suffering for more than the last 6 years.

The current LEADERSHIP was great when they started in the lab. Over the last 6 years, and especially RIGHT NOW, they are NOT qualified to move forward.

Hope this helps clarify where the unrest sits. Do some research and see for yourself.

Thunderforce1
Wednesday, 07/11/18 03:17:47 PM
Re: Auto1 post# 13582
0
Post # of 13591

You downers make no sense , if they were scammers and frauds why would the DOD get R18 passed for emerg use ? You don't think that they would have a clue and know if the stuff works ? Yes there are challenges like making quantities and storage and use but if they couldn't be over come the US gov't would not be involved and pushing for this to get passed nor would they be paying for it either .

Thunderforce1

Give thanks to GOD that we CAN laugh... Can you imagine?


Wednesday, 07/11/18 02:22:38 PM
Re: None
0
Post # of 13587

Auto 1 I just can't take you seriously , every time I go to read your posts I see that picture and just laugh .

YES.. You are catching on. They are posted because HISTORY & INTEGRITY is important. IF we don't learn from it, we will repeat it; or worse... Invest in it.

This latest 'collaboration' is a complete admission of FAILURE by psti LEADERSHIP to:

1) Establish and implement their 'in-house' manufacturing and distribution capabilities.
2) Select a partner or vendor that can deliver trials, data, enrollments and deadlines for indications.

IMHO.


hopester
Wednesday, 07/11/18 02:16:03 PM
Re: midastouch017 post# 13562
0
Post # of 13584

I've seen many dated news posts and wonder what the point is.
Could it be that 6 years after that news release , the message is nothings been done by Fisher?

But I suppose reading old news does help to refresh our memory if nothing else.

the indominable SPAM machine... you have to love that the article doesn't even name the 'spokesperson' from psti. I guess Zami and Yaky are WAT too busy to tout the latest news?

HAIFA, Israel, Sept. 27, 2012 (GLOBE NEWSWIRE)

...Worldwide Dispatch Distributor...off-the-shelf products... I guess that didn't work out so well, eh?

"These include the treatment of acute myocardial infarction (heart attack), lung disease, and bone marrow disease. These indications collectively represent multibillion dollar treatment markets."

How are these studies coming along, allo… don't remember them being highlights for the near-term pipeline... (thanks for the 2012 announcement)

PS - acute myocardial infarction (heart attack), lung disease, and bone marrow disease are NOT "indications" - more sloppy, mis-leading corporate communications.

Completely agree! - Eich & Blue, your doing a great service for the

under researched speculative investors everywhere. THIS WAS A NON-MATERIAL EVENT - NON-MATERIAL??

and Yaki is a BA Accountant...Scary. Slimy language in the article, just goes to show you who is leading this thing..... calculated and slimy. IMHO.

Material Event
Def: Important; affecting the merits of a case; causing a particular course of action; significant; substantial. A description of the quality of evidence that possesses such substantial Probative value as to establish the truth or falsity of a point in issue in a lawsuit.
A material fact is an occurrence, event, or information that is sufficiently significant to influence an individual into acting in a certain way, such as entering into a contract. In formal court procedures, a material fact is anything needed to prove one party's case, or tending to establish a point that is crucial to a person's position.

8-K - Investopedia
https://www.investopedia.com/terms/1/8-k.asp

An 8-K is a report of unscheduled material events or corporate changes at a company that could be of importance to the shareholders or the Securities and Exchange Commission (SEC). An 8-K is a report of unscheduled material events or corporate changes at a company that could be of importance to the shareholders or the Securities and Exchange Commission (SEC).

Material News - Investopedia
https://www.investopedia.com/terms/m/materialnews.asp

Material news includes information such as unusual corporate events, unexpected earnings results, stock splits and all other price-sensitive developments in a company, including proposed acquisitions, mergers, profit warnings and the resignation of directors.

EichKing
Wednesday, 07/11/18 11:54:25 AM
Re: bluehorsesho post# 13536
0
Post # of 13572

Blue.....you are right. Somethings gotta give. If there is nothing material by EOY, this stock is headed to RS territory. The empty promises won't cut it (like PLX-Immune mouse miracle) there is little market interest (as seen in the anemic average daily trading volume), leaving nothing but dilution.....if they can even achieve that. We sit in the low $1.20's for a reason.....and it isn't any "controller". Lack of cash.....plain and simple.

It's like whack-a-Mole today...

FDApproved
Wednesday, 07/11/18 10:22:08 AM
Re: None
0
Post # of 13571

ZZaatt...I Feel It Too ! We Going Higher Today IMO. :)

Good call zzatt...

You were right, you don't have a 'feeling'.

zzaatt
Wednesday, 07/11/18 10:11:27 AM
Re: None
0
Post # of 13570

I have a feeling that the pps might be going up today
(but I'm not really sure)

--------------------------------------------------------------------------------
"Can I hear a "MOLTO bellissimo" in the distance? I certainly hope so."

Smells like...

panic SPIN spirit!! allo must be getting hammered by the boiler room whipmaster.

FDApproved
Wednesday, 07/11/18 06:34:02 AM
Re: None
0
Post # of 13569

Why Short Volume is Important

PSTI....49%


Daily short volume, as reported by FINRA, is very misunderstood. Most people think daily short volume is just that — the volume that bearish investors put on to add to their short positions. A short glance at the change for total short positions reported bimonthly to the NASDAQ debunks that belief. Short volume isn’t the same as short interest.

In truth, much of the short volume is due to market makers selling into the market a few fractions of a second/minute/hour before they close their position by executing a broker order. Due to the fact that market makers cover many of their positions seconds later, much of the short volume isn’t necessarily an indication of useful bearishness.

The fact that a market maker is willing to sell and cover seconds later doesn’t do an investor holding the stock for the long term any good. The market maker could be bullish on the stock long term, and still be willing to short temporarily to satisfy a client request. Similarly, many market makers often have to go short in a fast market in order to fulfill their job of providing liquidity. Other market makers will widen their bid ask prices enough to get out of that scenario.

Nevertheless, short volume data is important — market makers are some of the most informed investors out there and they know the supply and demand equation of a stock better than almost everyone. Some do trade for their personal accounts and their shorting shows up in the short volume. Like other technical indicators, if enough people believe in something, that something can happen. It is also true that when factoring in the trend and potential randomness, a market maker could be potentially bearish if the short percent is substantially higher than average. The market maker could be potentially bullish if the short percent is lower than average.

To balance the two opposing factors and to prevent market makers from gaming the short data, an investor should use the site in the following: If short percent changes rapidly from day to day, or if short percent goes to one extreme (a monthly high or monthly low), it is a sign to pay attention to the fundamentals and technical of a stock more.

Volumebot helps ordinary investors gauge market maker sentiment by displaying daily short volume as reported by FINRA. We aggregate all of the short volume data and total volume data (but not short exempt volume due to its small size) reported by FINRA from ADF, FINRA; NASDAQ TRF, FINRA NYSE TRF; and ORF and display it in a simple chart and table format. Please note that due to the fact that not all volume is reported to FINRA, our total volumes will often be considerably smaller than the volumes listed on Yahoo or Google Finance.

https://volumebot.com/why-short-volume-is-important/

“From early on, our strategy was to build an in-house manufacturing facility,” said Pluristem’s president and co-CEO, Yaky Yanay. “Having achieved that, we are now in a unique position within the industry, and have a broad understanding of its needs.” -Yaki Yanay

Blue nailed this earlier... Spoken like a BA Account with NO sense of understanding.

SO...Riddle us this allo. If we have "in-house manufacturing", why will we not see "right-to-try" revenue booked in Q2. Remember, all of our indications are 1B+ markets. Surely there are patients that are demanding help for their un-met medical needs...

IF we are not helping MDs assist suffering patients right now, it borders on criminal greed and ethical failure. IMHO.

What say you?